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Background: Type 2 diabetes mellitus (T2DM) is a disease with high prevalence, associated with severe co-
morbidities as well as being a huge burden on public health. It is known that glycemic control decreases long-term
morbidity and mortality. The current standard therapy for T2DM is medical treatment. Several randomized
controlled trials (RCTs) performed in obese patients showed remission of T2DM after bariatric surgery. Recent RCTs
have shown bariatric procedures to produce a similar effect in non-morbidly and non-severely obese, insulin-
dependent T2DM patients suggesting procedures currently used in bariatric surgery as new therapeutical approach
in patients with T2DM. This study aims at investigating whether Roux-en-Y gastric bypass (RYGB) is an efficient
treatment for non-severely obese T2DM patients in terms of preventing long-term complications and mortality.
Methods: The DiaSurg 2 trial is a multicenter, open randomized controlled trial comparing RYGB including
standardized medical treatment if needed to exclusive standardized medical treatment of T2DM (control group).
The primary endpoint is a composite time-to-event endpoint (cardiovascular death, myocardial infarction, coronary
bypass, percutaneous coronary intervention, non-fatal stroke, amputation, surgery for peripheral atherosclerotic
artery disease), with a follow-up period of 8 years. Insulin-dependent T2DM patients aged between 30 and 65 years
will be included and randomly assigned to one of the two groups. The experimental group will receive RYGB and,
if needed, standardized medical care, whereas the control group will receive exclusive standardized medical care,
both according to the national treatment guidelines for T2DM. Statistical analysis is based on Cox proportional
hazards regression for the intention-to-treat population. Assuming a loss to follow-up rate of 20%, 200 patients will
be randomly allocated to the comparison groups. A total sample size of n = 400 is sufficient to ensure 80% power
in a two-tailed significance test at alpha = 5%.
Discussion: The DiaSurg2 trial will yield long-term data (8 years) on diabetes-associated morbidity and mortality in
patients with insulin-dependent T2DM receiving either RYGB or standardized medical care.
Trial registration: The trial protocol has been registered in the German Clinical Trials Register DRKS00004550.* Correspondence: beat.mueller@med.uni-heidelberg.de
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Rationale of the trial
According to WHO data, in 2000 the worldwide preva-
lence of type 2 diabetes mellitus (T2DM) was 2.8%, and in
2030 it is expected to rise to 4.4% [1,2]. Approximately 6
million people in Germany are currently suffering from
T2DM, among whom 2 million are insulin-dependent
[3,4]. A high proportion of these patients already suffer
from T2DM-related diseases, such as micro- and/or
macrovascular diseases resulting in neuro-, nephro-, retin-
opathy, myocardial infarction, and stroke [5,6]. The treat-
ment of these co-morbidities renders T2DM one of the
most expensive diseases in terms of public health expend-
iture in Germany [7]. Current guidelines recommend
medical therapy for the treatment of T2DM as the gold
standard [8,9]. It is known that sufficient glycemic control,
defined by the German Diabetes Association and Inter-
national Diabetes Foundation as HbA1c <6.5%, decreases
long-term morbidity [6,8-10]. Current guidelines with the
aim of lowering HbA1c-levels are therefore being
reconsidered, owing to the growing number of studies
showing an increased mortality rate for patients with
lower HbA1c [11-14].
Obesity is considered a risk factor for the development of
T2DM [15]. For patients with class 2 obesity (BMI >35 kg/
m2) with co-morbidities and patients with class 3 obesity
(BMI >40 kg/m2), bariatric surgery is recommended
when conservative attempts do not result in substantial
weight loss [16]. Existing evidence reports that bariatric
surgery not only leads to substantial weight loss, but
also to T2DM remission in 42% to 78% of the patients
who have undergone RYGB [17-19]. In addition,
T2DM-related diseases, such as cardiovascular diseases,
nephropathy, retinopathy, neuropathy, hyperlipidemia,
and hypertension, are supposed to be avoided or at least
delayed in their progress after metabolic surgery
[19-21]. In the Swedish Obese Subjects (SOS)-Study
35% of T2DM patients and 19% of patients suffering
from preoperative hypertension were still in remission
10 years after surgery [22]. The beneficial effects of
bariatric surgery on T2DM appeared shortly after sur-
gery, and before major weight loss, leading to the hy-
pothesis that weight loss alone is not solely responsible
for T2DM remission. In an experimental study, Rubino
et al. were able to prove that these effects are not
dependent on weight loss alone [23]. These findings led
surgeons to perform bariatric procedures on non-
severely obese patients (overweight and obesity class 1;
BMI 25–35 kg/m2) suffering from T2DM [21,24-26]. A
recent randomized controlled, single-center trial in pa-
tients with a BMI of 25–35 kg/m2 showed T2DM remis-
sion in 93% of patients following Roux-en-Y gastric
bypass (RYGB) and 47% of patients following laparo-
scopic gastric sleeve resection [27]. The effect of T2DMremission could therefore also be shown in non-severely
obese patients.
This randomized controlled multicenter trial assesses
whether bariatric surgery can be used as an alternative
in the primary care of T2DM, potentially leading to fewer
strokes or cardiovascular death and thus preventing long-
term morbidity and mortality well-known in T2DM
patients.
Objective
The aim of DiaSurg 2 is to investigate the time-to-event
of T2DM-induced morbidity and mortality after RYGB
compared to medical treatment according to the most
current clinical guidelines in patients with insulin-
dependent T2DM.
Trial locations
The DiaSurg 2 trial will be conducted in 13 German
centers which have expertise in bariatric surgery. So far,
the following German centers have already been de-
fined: University of Berlin, University of Dresden, Uni-
versity of Heidelberg, University of Kiel, University of
Lübeck, Vivantes Klinikum Spandau Berlin, St.-Martinus
Krankenhaus Düsseldorf, Nordwestkrankenhaus Frankfurt
am Main, Krankenhaus Sachsenhausen Frankfurt am
Main, Klinikum Gera, Wolfart Klinik Gräfelfing, Klinikum
Karlsruhe and Klinikum Memmingen. Additional recruit-
ment centers might participate in the study.
Methods/design
Trial design
Diasurg 2 trial is a multicenter, open randomized con-
trolled trial. Patients of the experimental group receive
RYGB surgery and standardized medical treatment if
needed. Patients in the control group receive exclusive
standardized medical treatment of T2DM.
Sample size
Two hundred patients per group (including the expected
dropouts) will be randomized for this trial, accounting
for a total of 400 patients.
Patient selection criteria
Eligible patients need to have a diagnosis of insulin-
dependent T2DM going back at least 3 months. Further-
more, they should have proof of at least one microvascu-
lar manifestation of T2DM (for example, nephropathy,
retinopathy, neuropathy) and have sufficient residual
endocrine pancreatic function, which is the premise for
autogenic glycemic control. Residual endocrine pancre-
atic function is assessed by glucagon-stimulated fasting
C-peptide laboratory tests with a minimum of 1.5 ng/mL.
Eligible participants must have a body mass index (BMI)
between 26 and 35 kg/m2, be aged between 30 and
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tive islet cell autoantibody testing will be required for pa-
tients who started insulin therapy within 1 year after
T2DM diagnosis to eliminate the risk of including patients
with autoimmune components (that is, type 1 diabetes
mellitus (T1DM) or latent autoimmune diabetes of adults
(LADA)). Inclusion and exclusion criteria are depicted in
Table 1.
Recruitment and timelines
Patients will be recruited by the Study Center of the
German Surgical Society (SDGC) at the University of
Heidelberg, Department of General, Visceral and Trans-
plant Surgery in cooperation with the Department of
Medicine I (Endocrinology) and Clinical Chemistry of
the University of Heidelberg and correspondingly at the
participating centers. Recruitment is planned to last
12 months. The first patient in to last patient out will be
120 months, and the proposed duration of the entire
trial is 132 months.
Randomization
Randomization will be performed after assessment of the
inclusion and exclusion criteria and informed consent of
the patient to participate in the study. Randomization will
be performed at a ratio of 1:1 for the two treatment groups,
using an online randomization tool (www.randomizer.at)
which enables block randomization and stratification for
each center. Four hundred patients will be recruited
according to the sample size calculation in order to prevent
random error and achieve sufficient strength for hypothesis
testing of the primary endpoint.Table 1 Inclusion and exclusion criteria
Inclusion criteria
Diagnosis of T2DM with insulin therapy for at least 3 months and an HbA1c
islet cell autoantibody testing will be required for patients that received insu
1 year after T2DM diagnosis
Proof of at least one microvascular manifestation of diabetes (for example, n
retinopathy, neuropathy)
Residual pancreatic function, which is the premise for autogenic glycemic co
stimulated fasting C-peptide laboratory tests with a minimum of 1.5 ng/mL
BMI 26–35 kg/m2
Age 30 to 65 yearsInterventions
Experimental group
A laparoscopic RYGB will be performed no later than
2 months after allocation to the experimental group. As
part of the standardized preoperative assessment, a
gastroscopy, laboratory tests, ultrasound of the abdo-
men, cardiological and endocrinological assessment will
be performed.
The operation technique is as follows: The patient is
positioned in the supine position 30° (reverse Trendelen-
burg) after a regular fasting time of 12 h. A single-shot
of antibiotic prophylaxis is given (according to local
standards of participating centers). Then a 15 mmHg
pneumoperitoneum through the left upper abdomen is
created. Next, five trocars are placed in the upper abdo-
men. The liver retractor is then positioned in the right
upper abdomen. Initially, the gastroesophageal junction
is identified. Then the stomach is transsected by the use
of linear staplers to build a pouch of 4–6 cm height and
14–16 mm width. The omentum majus can be transected
depending on the individual anatomy. At 70 cm from the
ligament of Treitz, an end-to-side gastroenterostomy is
performed using either a linear or circular stapler. To re-
construct the passage, a side-to-side jejuno-jejunostomy
150 cm from the gastrojejunostomy is performed
(Figure 1). The proximal anastomosis is then checked
for leaks by methylene blue.
After the operation, patients are hospitalized for ap-
proximately 5 days. Diabetic and hypertensive medica-
tion are paused and re-administered if needed according
to the endocrinologist’s decision. After dismissal, stan-
dardized medical therapy of T2DM is administeredExclusion criteria
of ≥7%; negative
lin therapy within
Type I diabetes mellitus or latent autoimmune
diabetes of adults (LADA)
ephropathy, T2DM on diet and/or oral medication
ntrol assessed by Heart failure (NYHA III-IV)
Pregnancy
Malignant disease in the past 5 years
History of major abdominal operation
Permanent glucocorticoid or other
immunosuppressive therapy
Pituitary disease/Morbus Addison
Renal failure (glomerular filtration rate < 45 ml/min)
Proof of any liver cirrhosis above grade A according
to the Child-Pugh-classification
Expected lack of compliance or inability to informed
consent
Figure 1 Visualization of the gastric bypass post surgery.
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betes Association [8,9].
Control group
Standardized medical therapy of T2DM and its co-
morbidities are defined as the use of the latest S3 Guide-
lines by the German Diabetes Association [8,9].
Study visits
From screening to last control 8 years after randomization
there will be 12 study visits assessing laboratory parame-
ters for diabetes, regular laboratory parameters, blood
pressure, resting 12-lead electrocardiogram amount of
medication, morbidity and mortality, especially nephropa-
thy, retinopathy, peripheral neuropathy, and quality of life
(Figure 2).
Risk-benefit ratio
RYGB is an established method in bariatric surgery, with
low mortality rates of 0.16% to 0.5% in experienced
hands [20,28]. Morbidity rates for all-cause complica-
tions range between 2% and 10% [20]. Long-term risk
for secondary disease due to malabsorption (deficiency
in vitamins, foliate, or iron balance) are known and are
managed by administering life-long vitamin supplemen-
tation [29]. Another possible side effect of RYGB is the
dumping syndrome. The risk of surgery for non-severely
obese diabetic patients is difficult to assess because there
are hardly any data. Due to the fact that patients are not
as obese as in bariatric surgery, both reduced morbidity
and reduced mortality rates are expected. In recentstudies involving non-severely obese patients suffering
T2DM, the postoperative mortality rate was found to be
0%, and only 1.2% if the operated patients needed revi-
sion due to postoperative complications [19,25,27,30].
Outcome
The chosen primary and secondary endpoints cover out-
comes from different perspectives (for example, patient,
surgeon, healthcare system), allowing for a comprehensive
evaluation of the surgical treatment of T2DM, especially
as to whether long-term T2DM-associated morbidity and
mortality can be diminished and which other factors, apart
from glycemic control, are dominant.
Primary endpoint
The primary endpoint is the time from randomization to
one of the composite events, including death from car-
diovascular causes, non-fatal myocardial infarction, cor-
onary artery bypass grafting, percutaneous coronary
intervention, non-fatal stroke, amputation, and surgery
for peripheral atherosclerotic artery disease during the
follow-up of at least 8 years according to the Steno 2
study. End-organ damage is also specified according to
the Steno2 study from Gaede et al. [31,32]. Together with
the expected accrual period of 2 years, this amounts to a
maximum follow-up period of 10 years. If none of the
above events are observed within the follow-up period,
the date of the last follow-up is censored.
Secondary endpoints
Secondary endpoints include the time to death from any
cause and the time to each component of the primary
endpoint. In addition, laboratory parameters for T2DM
(HbA1c, C-peptide and glucagon stimulated C-peptide,
fasting glucose, fasting insulin, oral glucose tolerance
test), regular laboratory parameters (that is, lipid pro-
files, serum creatinine, creatinine clearance) as well as
vitamins and micronutrients (vitamin B6, B12, folate
acid, and iron status) are assessed. Additional parame-
ters include the amount of medication (insulin dosage,
metformin, antihypertensive therapy, and so on), the as-
sessment of nephropathy (urine albumin excretion 24-h
urine sample), retinopathy (according to the EURODIAB
six-level grading scale), peripheral neuropathy (assessed
by biothesiometry of the big toe in both feet and ques-
tionnaire), healthcare cost and quality of life. Parameters
are assessed at 0, 3, 6, 12 months, and then yearly after
surgery (Figure 2).
Data management
All protocol-required information collected during the
trial is entered in the case report form (CRF) by the
investigator or a designated representative at the re-
spective participating center. Investigators are expected
Figure 2 Study flow for the duration of the entire trial.
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information is collected, preferably on the same day that
a trial participant is seen for an examination, treatment,
or any other trial procedure.
The completed CRF must be reviewed and signed by
the investigator named in the trial protocol or by a des-
ignated sub-investigator. After keeping a copy at the trial
center, the original CRF is sent to the University of
Heidelberg for data entry. Double data entry is carried
out to ensure the correct transfer of data from the CRF
to the database. Completeness, validity, and plausibility
of data are examined by validating programs that thereby
generate queries which need to be clarified by theinvestigator. At the end of the trial, the principle investiga-
tor will retain the original CRFs. All data are managed and
analyzed by the Study Center of the German Surgical So-
ciety (SDGC) at the University of Heidelberg in cooper-
ation with R&P GmbH (Burscheid, Germany) as contract
research organization.
Safety evaluation and reporting of adverse events
During and following a patient’s participation in the trial,
the investigator ensures that adequate medical care is
provided. The patient receives adequate treatment in any
clinical situation, including emergencies, and outcome of
the patient must be controlled. A serious adverse event is
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threatening, requires or prolongs hospitalization, results
in persistent or significant disability or incapacity, or re-
quires re-operation. From the day the patient has signed
informed consent until the regular end of the trial, or until
premature withdrawal of the patient, all serious adverse
events are documented and reported to the principal in-
vestigator within 24 h.Statistical methods
Sample size
The study, with seven components as used in the Steno 2
study [31,32], is designed to demonstrate the superiority
of the experimental group to the control group with re-
spect to the hazard ratio for a composite event. The
Steno2 study was used to estimate the rate of cardiovascu-
lar events we have to expect after 8 years of medical ther-
apy. A reduction of diabetes-associated morbidity from
20%, as reported in the Steno 2 study for intensified con-
servative T2DM treatment, to 10% for surgical treatment
will be defined as success and used for sample size calcu-
lation. Let pS and pC denote the cumulative incidence of
one or more components of the composite endpoint for
RYGB and standardized medical treatment, respectively.
For exponentially distributed event times, event rates of
pS = 0.10 and pC = 0.20 after 8 years correspond to a haz-
ard ratio of 0.472 in favor of surgical treatment [31]. At
the two-sided significance level of α = 5%, a total number
of 56 events is required to detect this effect with a power
of 80%. Assuming again exponentially distributed event
times, an accrual period of 2 years and a minimal
follow-up time of 8 years, the required number of pa-
tients to achieve this number of events is given by 336
in total, that is, 168 patients per treatment arm. Assum-
ing a loss to follow-up rate of 20%, 200 patients should
be randomly assigned to each intervention group (400
in total). This ensures sufficient power for the intention
to treat analysis (ITT) and the complete cases per
protocol (PP) analysis.Analysis of the primary endpoint
Each patient’s allocation to the different analysis popula-
tions (full analysis set according to the ITT principle, PP
analysis set, safety analysis set) will be defined prior to the
analysis. The allocation will be documented in the statis-
tical analysis plan prior to database closure. During the
data review, deviations from the protocol will be classified
as minor or major. Major deviations from the protocol will
lead to the exclusion of a patient from the PP analysis set.
The primary analysis will be performed using a Cox
proportional hazards regression (α = 5%, two-sided) with
covariates treatment group, age, duration of T2DM, and
a stratification for each center. Confirmatory analysiswill be based on the ITT population, with ICA-r imput-
ation for missing values [33].
Secondary analyses
A standard sensitivity analysis will be performed using
the PP analysis set. A further secondary analysis will be
based on a prioritized set of time-to-event variables,
ranging from death from any cause (highest priority),
stroke, myocardial infarction, amputation, coronary ar-
tery bypass grafting, percutaneous coronary intervention,
to peripheral atherosclerotic artery disease (lowest prior-
ity). Potential treatment benefit will be assessed by the
so-called proportion in favor of treatment [34], which is
a multivariate permutation test based on pair-wise com-
parisons of patients. The outcome of Patient X will be
said to be better than Patient Y if a decision can be
made based on pair-wise comparisons of the compo-
nents of the prioritized outcome in decreasing order.
Surgical treatment with standardized medical treatment
will be said to be better than exclusive standardized
medical treatment if the aggregate proportion in favor of
treatment is above 97.5 percentile of the proportions
obtained via simulation under the assumption of the null
hypothesis (that is, by permutation of the group mem-
bership of the patients).
All secondary variables will be analyzed descrip-
tively by tabulation of the measures of the empirical
distributions (means, standard deviations, quartiles).
For binary outcomes, relative frequencies will be
reported. Descriptive P values of the corresponding
group comparisons and associated 95% confidence
intervals will be given.
Safety measures
Safety analysis includes frequency of serious adverse
events and complications. Homogeneity of the study arms
will be described by comparing demographic data and
baseline values.
Withdrawals and stopping guidelines
Participants are free to withdraw from the trial at any
time without explanation. Insufficient recruiting of
participants will lead to premature closure, as will ex-
ceptionally frequently occurring adverse events due to
surgical interventions.
Data safety monitoring board
An independent Data and Safety Monitoring Board
(DSMB) will assess the reports of serious adverse events
and will inform the trial management about relevant im-
balances between the groups. The DSMB will meet at
least twice: once after randomization of one-third of pa-
tients, the second time after randomization of two-thirds
of the patients.
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Funding
The study is funded by the Manfred Lautenschläger Foun-
dation, Gaiberg, Germany and Covidien Services Europe
Ltd., Dublin, Ireland.
Monitoring
Clinical monitoring will be performed by R&P GmbH
(Burscheid, Germany), the contract research organization.
Monitoring procedures will be adapted to the study-
specific risks for patients and to the guidelines of Good
Clinical Practice of the International Conference on Har-
monisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH-GCP, E6) to ensure
patient safety and integrity of the clinical data, for ex-
ample, primary endpoint in adherence to the study proto-
col. Before starting, all participating centers will be
personally trained and introduced to all study-specific
procedures during a study initiation meeting where the
surgical and medical standards are depicted. In addition
there will be one video of the standardized operation as an
example for each surgeon at the centers. In addition sur-
geons must have performed at least 20 laparoscopic RYGB
to provide sufficient surgical expertise. Regular visits of
the participating centers will be performed to check
whether the operation is performed as demanded. These
visits are planned at all sites depending on the recruitment
rate and quality of the data (approximately one visit per
site and year). The investigator must allow the monitor
to look at all essential documents and must provide sup-
port at all times to the monitor. Clinical source data
verification (SDV) is planned for all clinical items. The
extent of further SDV and/or the frequency of monitor-
ing visits will be adapted for individual centers in case
of insufficient quality of data or if common protocol vi-
olations are observed. In addition to standard operating
procedures, all procedures will be predefined in a study-
specific monitoring manual.
Ethical considerations
The surgical procedure examined in this trial is well
established and in current daily use. T2DM is associated
with high long-term morbidity and mortality [31]. In
obese patients, bariatric surgery showed a remission of
T2DM in 42% to 78% of patients [17-19]. In obese pa-
tients, mortality of RYGB was about 0.16% to 0.5%, and
although the operative risk in obese patients is described,
mortality and morbidity rates are expected to be lower in
non-severely obese patients [20,28]. Respectively, the op-
erative risk is ethically justifiable considering long-term
morbidity and mortality. By comparing conventional med-
ical care to surgical treatment point-by-point, differences
in the development of T2DM-associated symptoms are
possible. Each individual patient in the interventiongroup justifiably has the potential to end further insulin
treatment for T2DM and thus possibly avoid T2DM-
associated co-morbidities. Each patient in the control
group will receive standardized medical treatment
according to the latest S3 guidelines and thus have no
handicap by participating in the study. Participants in
the control group will be treated by use of the latest S3
Guidelines set forth by the German Diabetes Associ-
ation [9]. If the study confirms evidence in improving
diabetic symptoms in the experimental group and con-
sequently health-insurance funds refund costs for surgi-
cal treatment of T2DM, patients randomized within the
medical treatment group will be able to switch to the
surgery group. Postoperatively, patients will be exam-
ined every year for possible side-effects of the surgery,
including an assessment of their vitamin and nutritional
status.
Good clinical practice
The trial is planned and will be conducted and analyzed
according to all relevant national and international rules
and regulations (ICH-GCP, Declaration of Helsinki 2008).
Registration
The trial protocol has been registered with the German
Clinical Trials Register (DRKS) under the registration
number DRKS00004550.
Discussion
Surgical treatment of T2DM is a subject that has been
discussed in-depth in recent literature [18,19,35-37].
T2DM remission was observed as occurring before sub-
stantial weight loss [18,38]. However, the mechanisms
leading to T2DM remission after surgery have not yet
been fully understood. Potential explanations include the
changed expressions of gastrointestinal hormones, which
result in an improved insulin resistance level, and im-
proved excretion of insulin from the beta-cells in the
pancreas [39-41]. Currently, however, there is no single
satisfactory explanation for the metabolic mechanisms
that lead to T2DM remission after bariatric surgery [42].
Nevertheless, T2DM remission was observed in a high
proportion of obese patients (42-78%) after bariatric sur-
gery [17-19]. Thus, bariatric surgery is, to some extent,
discussed as being part of the therapy regimen for
T2DM which may lead to a paradigm shift in the treat-
ment of T2DM, a disease with high prevalence, severe
associated co-morbidities as well as being a huge burden
on public health [35].
Since it is known that good glycemic control decreases
long-term morbidity, a substantial reduction of mortality
and morbidity can be expected [6,10]. Several random-
ized controlled trials (RCTs) have focused on diabetes
remission, assessed mostly by HbA1c and fasting
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ever, diabetes-associated morbidity and mortality were
not the subjects of those studies because the follow-up
period of 12 to 24 months was too short to assess them
as endpoints. These studies have proven that the suc-
cessful implementation of bariatric surgery for the treat-
ment of non-severely obese patients suffering from
T2DM is safe and feasible. Since trials on the long-term
effects of bariatric surgery on T2DM in a multicenter
setting are not available, the present study was designed
not to use HbA1c as a surrogate parameter, but as time-
to-event of diabetes-associated mortality or morbidity
with an appropriate follow-up of 8 years.
The goal of the study is to assess whether RYGB in-
cluding standardized medical treatment is superior to
exclusive standardized medical treatment of T2DM.
Both treatment groups will receive standardized medical
treatment according to the latest German S3 guidelines.
The endocrinologists at the participating centers agreed
on the standardized medical treatment taking the results
of the ACCORD study into account [43]. Aggressive
insulin dosage will not be performed in any group. Pa-
tients receiving RYGB will need close monitoring of
dyslipidemia, hypertension, and hypoglycemia and corre-
sponding adaption of the prescribed treatment postopera-
tively. To ensure this an additional follow-up is scheduled
for these patients at 1 month after RYGB.
Sample size calculation and the primary endpoint were
based on the Steno 2 study by Gaede et al., who showed
a reduction from 30% to 20% of diabetes-associated mor-
tality and morbidity in an intensified medical treatment
arm [31]. A further reduction of diabetes-associated mor-
bidity to 10% for surgical treatment was defined as success
and used for sample size calculation. To be able to have
enough macrovascular complications inclusion and exclu-
sion criteria, for example, microvascular manifestation of
T2DM, were adapted to the Steno 2 study to allow for a
similar patient population resulting in a study population
with high risk to develop macrovascular complications.
Although microvascular and macrovascular complications
do have different pathogenesis we could use the data from
the Steno 2 study to estimate the rate of macrovascular
complications in patients with T2DM and microvascular
complications at time of randomization. This allows the
achievement of sufficient statistical power with a relatively
small sample size.
Macrovascular diseases are assessed as time from
randomization to one of the components of the primary
endpoint including death from cardiovascular causes,
non-fatal myocardial infarction, coronaryartery bypass
grafting, percutaneous coronary intervention, non-fatal
stroke, amputation, and surgery for peripheral atheroscler-
otic artery disease. Microvascular diseases will be assessed
by corresponding laboratory testing; that is, nephropathy(urine albumin excretion 24-h urine sample), retinopathy
(according to the EURODIAB six-level grading scale), and
peripheral neuropathy (assessed by biothesiometry of the
big toe in both feet plus questionnaire).
It is not known how long the effects of surgery on dia-
betes remission or diabetes-associated co-morbidities
last, and if or when T2DM will again require intensified
medical treatment. First publications show that in a high
proportion of patients the effect is long-lasting. Jimenez
et al. assessed 153 obese patients after a mean follow-up
of 35 months. In 75.2% of patients, remission of T2DM
was achieved at 12 months, and in 12.1% of the patients
T2DM recurred [44]. Arterburn et al. found in 4,434
obese patients having had gastric bypass in a multisite
study a median duration of remission of T2DM of
8.3 years [45]. In a further analysis of T2DM incidence,
Carlsson et al. analyzed 1,658 patients who received bar-
iatric surgery versus 1,771 matched obese controls from
the SOS study. They found a statistically significant
difference namely, that patients who received bariatric
surgery were less likely to develop T2DM. The incidence
in the control group was 28.4 cases per 1,000 person-
years and 6.8 cases per 1,000 person-years in the surgical
group [46]. It remains to be discussed whether the bene-
fits of bariatric surgery on T2DM outweighs the risk of
the operation. Conservative therapy, however, also has a
mortality rate. It was shown by Sjöström et al. in an
SOS trial involving 4,047 patients receiving bariatric
surgery compared to 2,037 matched controls receiving
conservative treatment that bariatric surgery reduces
mortality in obese patients significantly, with a hazard
ratio of 0.76 [47].
Adjustable gastric banding, RYGB, laparoscopic gastric
sleeve resection, biliopancreatic diversion, and duodeno-
jejunal bypass have been used for the control of T2DM
in non-severely obese patients. All of them show positive
effects in the amelioration of T2DM, while gastric
banding seems to be the least and biliopancreatic diver-
sion the most effective treatment [17,27,48-50]. In this
study RYGB was chosen as the operative technique since
it seemed to have the best ratio of risk and benefit in
terms of T2DM remission and postoperative mortality
and morbidity, for example, severe malabsorption
resulting in vitamin and nutritive deficiencies [20,27].
In addition to reduced mortality and morbidity, re-
duced costs can be expected, as assessed by Makary
et al., who analyzed 2,235 obese patients with T2DM who
underwent bariatric surgery. Compared to preoperative
annual healthcare costs of $6,376 in the first year after
surgery, costs for T2DM treatment increased by 9.7%
but decreased in the third year by 70.5%. Makary et al.
concluded that even with the additional cost of the oper-
ation, overall healthcareexpenditure for patients who re-
ceived bariatric surgery were lower [51].
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http://www.trialsjournal.com/content/14/1/183If the present study is successful, it will contribute to a
possible paradigm shift in T2DM treatment, which will be
the implementation of surgery for the treatment of
T2DM. This randomized controlled multicentre trial will
assess - for the first time in Europe and in a multicenter
setting - whether RYGB is an efficient method to prevent
long-term complications in non-severely obese patients
with T2DM, and whether it can be used as an alternative
in the primary care of T2DM, thereby potentially leading
to less strokes or cardiovascular death and thus preventing
well-known long-term morbidity and mortality in T2DM
patients.
Trial status
Recruitment will begin in Q2 2013.
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